• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Anaplastic lymphoma kinase inhibitor development: enhanced delivery to the central nervous system.

作者信息

Hida Toyoaki

机构信息

Lung Cancer Center, Central Japan International Medical Center, Minokamo, Gifu, Japan.

出版信息

Transl Lung Cancer Res. 2023 Aug 30;12(8):1822-1825. doi: 10.21037/tlcr-23-43. Epub 2023 Jul 31.

DOI:10.21037/tlcr-23-43
PMID:37691872
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10483074/
Abstract
摘要

相似文献

1
Anaplastic lymphoma kinase inhibitor development: enhanced delivery to the central nervous system.间变性淋巴瘤激酶抑制剂的研发：增强向中枢神经系统的递送
Transl Lung Cancer Res. 2023 Aug 30;12(8):1822-1825. doi: 10.21037/tlcr-23-43. Epub 2023 Jul 31.
2
Brigatinib and lorlatinib: their effect on ALK inhibitors in NSCLC focusing on resistant mutations and central nervous system metastases.布加替尼和劳拉替尼：它们对非小细胞肺癌中 ALK 抑制剂的影响，重点关注耐药突变和中枢神经系统转移。
Jpn J Clin Oncol. 2021 Jan 1;51(1):37-44. doi: 10.1093/jjco/hyaa192.
3
Evaluation of Lorlatinib Cerebrospinal Fluid Concentrations in Relation to Target Concentrations for Anaplastic Lymphoma Kinase (ALK) Inhibition.评估洛拉替尼在中枢神经系统中的浓度与间变性淋巴瘤激酶（ALK）抑制的靶浓度的关系。
J Clin Pharmacol. 2022 Sep;62(9):1170-1176. doi: 10.1002/jcph.2056. Epub 2022 Apr 27.
4
Treatment Optimization for Brain Metastasis from Anaplastic Lymphoma Kinase Rearrangement Non-Small-Cell Lung Cancer.治疗间变性淋巴瘤激酶重排非小细胞肺癌脑转移
Oncol Res Treat. 2019;42(11):599-606. doi: 10.1159/000502755. Epub 2019 Sep 17.
5
Management of CNS disease in ALK-positive non-small cell lung cancer: Is whole brain radiotherapy still needed?ALK阳性非小细胞肺癌中枢神经系统疾病的管理：全脑放疗仍有必要吗？
Cancer Radiother. 2019 Sep;23(5):432-438. doi: 10.1016/j.canrad.2019.03.009. Epub 2019 Jul 19.
6
Novel derivatives of anaplastic lymphoma kinase inhibitors: Synthesis, radiolabeling, and preliminary biological studies of fluoroethyl analogues of crizotinib, alectinib, and ceritinib.新型间变性淋巴瘤激酶抑制剂衍生物：克唑替尼、阿来替尼和塞瑞替尼的氟乙基类似物的合成、放射性标记及初步生物学研究。
Eur J Med Chem. 2019 Nov 15;182:111571. doi: 10.1016/j.ejmech.2019.111571. Epub 2019 Aug 9.
7
The characteristics of cerebrospinal fluid anaplastic large cells in a patient with primary leptomeningeal anaplastic large cell lymphoma.患者原发性软脑膜间变性大细胞淋巴瘤的脑脊液中出现间变性大细胞的特征。
Clin Chim Acta. 2022 Dec 1;537:46-50. doi: 10.1016/j.cca.2022.09.029. Epub 2022 Oct 13.
8
Real-World Treatment Patterns and Progression-Free Survival Associated with Anaplastic Lymphoma Kinase (ALK) Tyrosine Kinase Inhibitor Therapies for ALK+ Non-Small Cell Lung Cancer.真实世界中治疗模式与间变性淋巴瘤激酶（ALK）酪氨酸激酶抑制剂治疗ALK+非小细胞肺癌的无进展生存期。
Oncologist. 2020 Oct;25(10):867-877. doi: 10.1634/theoncologist.2020-0011. Epub 2020 Jul 23.
9
P-glycoprotein Mediates Ceritinib Resistance in Anaplastic Lymphoma Kinase-rearranged Non-small Cell Lung Cancer.P-糖蛋白介导间变性淋巴瘤激酶重排非小细胞肺癌对色瑞替尼的耐药性。
EBioMedicine. 2015 Dec 12;3:54-66. doi: 10.1016/j.ebiom.2015.12.009. eCollection 2016 Jan.
10
Success of Crizotinib Combined with Whole-Brain Radiotherapy for Brain Metastases in a Patient with Anaplastic Lymphoma Kinase Rearrangement-Positive Non-Small-Cell Lung Cancer.克唑替尼联合全脑放疗治疗间变性淋巴瘤激酶重排阳性非小细胞肺癌脑转移患者的疗效
Case Rep Oncol. 2018 Nov 29;11(3):777-783. doi: 10.1159/000492150. eCollection 2018 Sep-Dec.

引用本文的文献

1
Efficacy of alectinib in lung adenocarcinoma patients with different anaplastic lymphoma kinase () rearrangements and co-existing alterations-a retrospective cohort study.阿来替尼在不同间变性淋巴瘤激酶（ALK）重排及共存改变的肺腺癌患者中的疗效——一项回顾性队列研究
Transl Lung Cancer Res. 2023 Dec 26;12(12):2505-2519. doi: 10.21037/tlcr-23-658. Epub 2023 Nov 22.

本文引用的文献

1
ALK inhibitors in ALK-rearranged non-small cell lung cancer with and without brain metastases: systematic review and network meta-analysis.ALK 抑制剂治疗伴有和不伴有脑转移的 ALK 重排非小细胞肺癌的系统评价和网络荟萃分析。
BMJ Open. 2022 Sep 19;12(9):e060782. doi: 10.1136/bmjopen-2022-060782.
2
Evaluation of Lorlatinib Cerebrospinal Fluid Concentrations in Relation to Target Concentrations for Anaplastic Lymphoma Kinase (ALK) Inhibition.评估洛拉替尼在中枢神经系统中的浓度与间变性淋巴瘤激酶（ALK）抑制的靶浓度的关系。
J Clin Pharmacol. 2022 Sep;62(9):1170-1176. doi: 10.1002/jcph.2056. Epub 2022 Apr 27.
3
ASCEND-7: Efficacy and Safety of Ceritinib Treatment in Patients with ALK-Positive Non-Small Cell Lung Cancer Metastatic to the Brain and/or Leptomeninges.ASCEND-7：塞瑞替尼治疗脑转移和/或脑膜转移的 ALK 阳性非小细胞肺癌患者的疗效和安全性。
Clin Cancer Res. 2022 Jun 13;28(12):2506-2516. doi: 10.1158/1078-0432.CCR-21-1838.
4
Isolated progression of miliary brain metastasis in a patient with stable lung adenocarcinoma successfully treated with whole-brain radiotherapy: A case report.一名肺腺癌病情稳定的患者发生孤立性粟粒性脑转移，经全脑放疗成功治疗：病例报告
eNeurologicalSci. 2021 Aug 30;25:100366. doi: 10.1016/j.ensci.2021.100366. eCollection 2021 Dec.
5
Head to head evaluation of second generation ALK inhibitors brigatinib and alectinib as first-line treatment for ALK+ NSCLC using an systems biology-based approach.使用基于系统生物学的方法对第二代ALK抑制剂布加替尼和阿来替尼作为ALK阳性非小细胞肺癌一线治疗进行头对头评估。
Oncotarget. 2021 Feb 16;12(4):316-332. doi: 10.18632/oncotarget.27875.
6
Advancing brain barriers RNA sequencing: guidelines from experimental design to publication.推进脑屏障 RNA 测序：从实验设计到发表的指南。
Fluids Barriers CNS. 2020 Aug 18;17(1):51. doi: 10.1186/s12987-020-00207-2.
7
Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial.劳拉替尼用于治疗具有ALK或ROS1重排的非小细胞肺癌：一项国际多中心、开放标签、单臂首次人体1期试验。
Lancet Oncol. 2017 Dec;18(12):1590-1599. doi: 10.1016/S1470-2045(17)30680-0. Epub 2017 Oct 23.
8
First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study.一线塞瑞替尼与铂类化疗用于晚期ALK 重排非小细胞肺癌（ASCEND-4）：一项随机、开放标签、III 期研究。
Lancet. 2017 Mar 4;389(10072):917-929. doi: 10.1016/S0140-6736(17)30123-X. Epub 2017 Jan 24.
9
Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial.色瑞替尼在间变性淋巴瘤激酶（ALK）重排的非小细胞肺癌患者中的活性与安全性（ASCEND-1）：多中心、开放标签、1期试验的更新结果
Lancet Oncol. 2016 Apr;17(4):452-463. doi: 10.1016/S1470-2045(15)00614-2. Epub 2016 Mar 11.
10
P-glycoprotein Mediates Ceritinib Resistance in Anaplastic Lymphoma Kinase-rearranged Non-small Cell Lung Cancer.P-糖蛋白介导间变性淋巴瘤激酶重排非小细胞肺癌对色瑞替尼的耐药性。
EBioMedicine. 2015 Dec 12;3:54-66. doi: 10.1016/j.ebiom.2015.12.009. eCollection 2016 Jan.